• Link to LinkedIn
  • Link to X
  • Link to Facebook
  • Contact Us
  • Careers
Spermosens AB
  • Technology
    • IP Status
    • White Paper
  • Team
    • Core Team
    • Board
    • Partners
  • About us
    • Milestones
    • Sustainable Development Goals
    • Sponsorships & Memberships
    • Advisory Board Members
  • Investors
    • TO 6
    • The Share
    • Financial Calendar
    • Press & Media
    • Financial Reports
    • Board
    • Corporate Governance
  • Press & Media
    • Press Releases
    • Presentations
    • Interviews
    • Articles
    • Photos & Logo
  • ART Academy
  • Menu Menu

Spermosens AB (publ)YEAR-END REPORT JANUARY – DECEMBER 2025 – CORRECTED

Correction: The Year-End Report referred to in the press release published earlier today was inadvertently omitted. The complete report is now attached.

We have reached important results staying uncompromisingly focused on what matters and refusing to be distracted. By replacing estimation with evidence, we are turning a great invention into a great product.

 

1 JANUARY – 31 DECEMBER 2025

SIGNIFICANT EVENTS DURING THE QUARTER 

22-10-2025 – Spermosens receives patent approval in Canada

03-11-2025 – Spermosens receives patent approval in Mexico

04-11-2025 – Spermosens receives patent approval in Israel

18-11-2025 – Spermosens receives patent approval in China

08-12-2025 – Spermosens announces outcome of exercise of warrants series TO 4

09-12-2025 – Spermosens shares progress and plans for partner-driven commercialization

 

SIGNIFICANT EVENTS AFTER THE END OF THE INTERIM PERIOD

16-01-2026 – Spermosens and Sapyen sign Memorandum of Understanding to advance male fertility diagnostic

26-01-2026 – Spermosens and RSI sign Memorandum of Understanding to advance male fertility diagnostics in the US

FINANCIAL INFORMATION

 

 

2025

2024

2025

2024

Amounts in SEK thousand

 

Q4

Q4

Full Year

Full Year

Net sales

 

–

–

–

–

Operating profit/loss

 

-2 121

-2 373

-9 201

-9 163

– Whereof activated work for own account

318

408

837

4 120

Cash and cash equivalents

 

6 836

659

6 836

659

Total Cash flow

 

-2 236

530

6 177

-3 833

Equity end of period

 

32 411

27 345

32 411

27 345

Balance sheet total

 

33 940

31 044

33 940

31 044

Equity/assets ratio,%

 

95

88

95

88

Liquidity ratio,%

 

510

47

510

47

No. of shares

 

3 173 024 065

283 607 120

3 173 024 065

283 607 120

Weighted average number of shares, adjusted for dilution effect

 

3 173 024 065

283 607 120

2 537 686 452

187 569 007

Earnings per share, SEK

 

-0,001

-0,01

-0,004

-0,04

Number of employees at end of period

 

4

3

4

3

 

 

 

 

 

CEO STATEMENT

 

When I joined Spermosens in May 2024, I saw a company with a unique technological foundation and a robust patent portfolio. However, great inventions only become great products when they serve a clear, undeniable purpose. Since then, we have disciplined every effort toward turning that potential into tangible progress. Today, we are not only developing a diagnostic tool; we are addressing a fundamental gap in reproductive healthcare.

Infertility is a global challenge, with male factors contributing to roughly half of all cases. For too long, the industry has relied on limited assessments that leave couples and clinicians uncertain. Our clinical study completed in June was a turning point. The results demonstrated a correlation between JUNO binding, which measures the sperm’s functional ability to bind to the egg, and fertilization rates. By providing the only method that measures this critical biological interaction, we move from estimation to evidence. The data strengthen our position as we aim to give clinicians clear guidance and help couples with the answers they need.

Innovation requires protection, and this year we successfully expanded our intellectual property foundation. Our core patent is now granted in key global markets, including Europe, North America, China, Japan and Australia. This creates a secure, long-term framework for our commercialization efforts.

We are making significant progress toward bringing JUNO-Checked to major markets. Our goal is to reach clinics, laboratories and patients through innovative companies who combine strong commercial networks with a focus on male infertility and patient-centric care. We are in contact with several companies in the US, Europe and Asia. Our Memoranda of Understanding with Sapyen and RSI Technology Group are important steps forward. While these agreements are indicative, they provide the structure to map our technology into our potential partners' clinical networks. This process is instrumental in aligning our technical requirements with their commercial operations as we move toward formal licensing and partner agreements.

The progress we have made is the work of a small team of extraordinary people. We have reached important results staying uncompromisingly focused on what matters and refusing to be distracted. This strict discipline has enabled us be fast, precise and ready to bring our innovative solution to the market while maintaining a low burn-rate. We have directed our capital away from overhead and into a potential solution in reproductive healthcare.

To fuel our mission, we secured a strategic investment in the first quarter of 2025. The support from investors in Germany, Scandinavia and the United States provides validation of our strategy.

The future of Spermosens lies in our ability to integrate our technology into modern laboratories and clinics. Development of our Generation 3 system is progressing according to plan and is expected to be completed first half of 2026. The system is designed for higher throughput, faster results and ease of use. We are now preparing for technical and clinical validation of the third-generation platform. Our goal is to meet the specifications required for successful commercialization and integration into routine fertility workflows.

Throughout 2025, our strategy has aligned clinical evidence, product development and partnership discussions. What motivates me most is the dedication and focus of our team as we transform scientific milestones into solutions that make a meaningful difference for people who are trying to start families. This year, we are dedicated to the completion and validation of Generation 3 and advancing our partnership frameworks into commercial reality. We are building a company that creates long term value for our shareholders by solving one of the most significant and personal challenges of our time.

 

A person in a suit

A close-up of a signature

Description automatically generated

Tore Duvold, CEO of Spermosens AB

 

 

Regulatory

Attachments

  • 📎 Spermosens AB (publ)YEAR-END REPORT JANUARY – DECEMBER 2025 - CORRECTED PDF
  • 📎 SPERMOSENS AB publ YEAR-END REPORT JANUARY-DECEMBER 2025 PDF
← Back to press releases
11 February, 2026
Share this entry
  • Share on X
  • Share on LinkedIn
  • Share by Mail
https://www.spermosens.com/wp-content/uploads/2021/08/Spermosens_Logo_RGB-1-1024x364.png 0 0 Spermosens https://www.spermosens.com/wp-content/uploads/2021/08/Spermosens_Logo_RGB-1-1024x364.png Spermosens2026-02-11 08:58:432026-11-14 22:24:46Spermosens AB (publ)YEAR-END REPORT JANUARY – DECEMBER 2025 – CORRECTED

Press releases

  • 12 November, 2026 Regulatory Spermosens AB (publ) INTERIM REPORT JULY – SEPTEMBER 2026 Our focus is shifting from development to go-to-market preparations   1 JULY – 30… Read more
  • 9 November, 2026 Regulatory Leading Australian fertility group Genea to run first independent clinical study of JUNO-Checked Spermosens AB has signed a collaboration framework agreement with Genea Pty Ltd (Genea), one of… Read more
  • 20 October, 2026 Spermosens presents JUNO-Checked at ASRM 2026 in Baltimore Spermosens AB (publ) (“Spermosens” or the “Company”) announces that the Company has been admitted to the … Read more
  • 1 September, 2026 Regulatory Bulletin from Extraordinary General Meeting in Spermosens AB (publ) Today, September 1, 2026, the Extraordinary General Meeting was held. Below is a summary of the… Read more
  • 21 August, 2026 Spermosens AB (publ) to Host Live Q&A Webcast on 27 August 2026 Spermosens AB (publ) ("Spermosens" or the "Company") today announces that it will host a live… Read more
  • 20 August, 2026 Regulatory Spermosens AB (publ) INTERIM REPORT APRIL – JUNE 2026 In the second quarter of 2026, we saw recruitment into its Generation 3 clinical validation study… Read more

Spermosens AB

MEDICON VILLAGE
Scheeletorget 1
223 81 Lund, Sweden

 

  • Quality & Regulatory
  • Privacy Policy
Cookie settings
© Copyright 2025 - Spermosens AB | Photos from Unsplash.com | Icons from Flaticon.com | Website by 8612 Hemsidesproduktion
  • Link to LinkedIn
  • Link to X
  • Link to Facebook
Link to: Spermosens AB (publ)YEAR-END REPORT JANUARY – DECEMBER 2025 Link to: Spermosens AB (publ)YEAR-END REPORT JANUARY – DECEMBER 2025 Spermosens AB (publ)YEAR-END REPORT JANUARY – DECEMBER 2025 Link to: Spermosens AB (publ) to Host Live Q&A Webcast Following Recent Progress Link to: Spermosens AB (publ) to Host Live Q&A Webcast Following Recent Progress Spermosens AB (publ) to Host Live Q&A Webcast Following Recent Progress
Scroll to top Scroll to top Scroll to top

This site uses cookies. Please accept the settings or adjust them to your personal preference.

Accept settingsHide this notificationSettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide the notification